摘要
目的:评估检测血清IL-17在多发性骨髓瘤(MM)诊断、预后及疗效判断方面的应用价值。方法:ELISA法检测21例MM患者(初诊7例,复发9例,平稳期5例)和15名健康体检者的IL-17、VEGF、TNF-α和β2-m血清含量,并分析IL-17与VEGF、TNF-α和β2-m水平之间的相关性。结果:初诊及复发MM患者的IL-17、VEGF、TNF-α和β2-m水平显著高于平稳期MM患者和对照组,差异有统计学意义,P<0.05。平稳期MM患者与对照组之间差异无统计学意义,P>0.05。IL-17、VEGF、TNF-α和β2-m的血清水平随着临床分期的增加而呈增高趋势,且除了IL-17外,Ⅲ期MM患者的VEGF、TNF-α和β2-m的血清水平均显著高于Ⅱ期患者,Ⅱ期患者显著高于Ⅰ期患者,差异均有统计学意义,P<0.05;ⅢA期MM患者的IL-17水平虽高于ⅡB期MM患者,但差异无统计学意义,P>0.05。比较各期患者A和B亚型各因子水平差异发现,除β2-m外,其余因子水平均是B亚型显著高于A亚型,差异有统计学意义(P<0.05),而ⅢB期MM患者的β2-m水平虽高于ⅢA期MM患者,但差异无统计学意义,P>0.05。MM患者的IL-17水平与TNF-α(r=0.918)、VEGF(r=0.862)和β2-m(r=0.953)均呈正相关,P值均<0.01。结论:IL-17能够促进血管新生并与MM进展相关,可作为MM临床分期、预后及疗效判断的潜在指标。
OBJECTIVE：To assess the diagnosis, prognosis and therapeutic evaluation of determination of serum lev- els of IL-17 in patients with multiple myeloma （MM）. METHODS： Serum levels of IL-17, VEGF, TNF-α, and β2-m were measured in 7 patients with primary MM, 9 patients with relapse MM,5 patients with remission MM and 15 controls with ELISA,and the correlation of IL-17 and VEGF, TNF-α, β2-m was detected. RESULTS： The levels of IL-17, VEGF, TNF-α,and β2-m in the sera of patients with primary MM and patients with relapse MM were significantly higher than those in patients with remission MM and controls （P〈0. 05）. However the difference between patients with remission MM and controls did not reach statistical significance （P》0.05）. The serum levels of IL-17,VEGF,TNF a and β2-MG increased from stage I to stage Ⅲ ,and the difference in the consecutive stages reached statistical significance （P〈0. 05）. The serum levels of IL-17 in patients with MM stage Ⅲ A were higher than those in patients with MM stage ⅡB, the difference in two stages did not reach statistical significance （P〉0. 05）. Detailed analysis revealed that these cytokine lev- els in patients with MM group B were significantly higher than those in group A （P〈0.05） ,except β2-MG. The levels of others between stage ⅢA and stage ⅢB did not reach statistical significance （P〉0. 05）. Serum values of IL-17 in MMpatients correlated positively not only with TNF-a（r=0. 918） and VEGF（r=0. 862）,but also with 132-m（r=0. 953） P values less than 0.01. CONCLUSIONS ： These results suggest that IL-17 plays a role in the promotion of angiogenesis and is associated with disease progression in MM. It may be a potential marker for determination of clinical stage, prognosis and efficacy in MM patients.
出处
《中华肿瘤防治杂志》
CAS
北大核心
2012年第19期1507-1510,共4页
Chinese Journal of Cancer Prevention and Treatment
基金
山东大学科技发展计划(201101117)
山东省医药卫生科技发展计划面上项目(2011HW010)
山东大学卫生局科技计划(2008-09)
